Antihistamines in late-phase clinical development for allergic disease

Expert Opinion on Investigational Drugs

Volumn 11, Issue 2, 2002, Pages 259-273

  Salmun, Luis M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Allergic rhinitis; Asthma; Chronic idiopathic urticaria; Drug interaction; Histamine receptor antagonist therapy; Inflammation

Indexed keywords

3 [4 (8 FLUORO 5,11 DIHYDROBENZ[B]OXEPINO[4,3 B]PYRIDIN 11 YLIDENE)PIPERIDINO]PROPIONIC ACID; ACRIVASTINE; ANTIHISTAMINIC AGENT; ASTEMIZOLE; AUTACOID; AZATADINE; AZELASTINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CETIRIZINE; CHLORPHENIRAMINE; DECONGESTIVE AGENT; DESLORATADINE; DIPHENHYDRAMINE; EFLETIRIZINE; EPINASTINE; ERYTHROMYCIN; FEXOFENADINE; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROXYZINE; KETOCONAZOLE; LEVOCETIRIZINE; LORATADINE; MIZOLASTINE; NORASTEMIZOLE; PROMETHAZINE; RUPATADINE; TERFENADINE; UNINDEXED DRUG; NONSTEROID ANTIINFLAMMATORY AGENT;

ALLERGIC CONJUNCTIVITIS; ALLERGIC DISEASE; ALLERGIC RHINITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICHOLINERGIC EFFECT; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC URTICARIA; CLINICAL STUDY; COMORBIDITY; CONTROLLED STUDY; DOSE RESPONSE; DROWSINESS; DRUG ACTIVITY; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; HISTAMINE RELEASE; HUMAN; HUMAN CELL; MEDIATOR RELEASE; MOUSE; NONHUMAN; NOSE CONGESTION; PATHOPHYSIOLOGY; REVIEW; SEDATION; XEROSTOMIA; CHRONIC DISEASE; CLINICAL TRIAL; HYPERSENSITIVITY; IMMUNOLOGY; PERENNIAL RHINITIS; TOPICAL DRUG ADMINISTRATION; URTICARIA;

ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASTHMA; CHRONIC DISEASE; CLINICAL TRIALS; CONJUNCTIVITIS, ALLERGIC; HISTAMINE H1 ANTAGONISTS; HUMANS; HYPERSENSITIVITY; RHINITIS, ALLERGIC, PERENNIAL; URTICARIA;

EID: 0036172118     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.2.259     Document Type: Review

References (114)

1. Pharmacotherapy to prevent the complications of allergic rhinitis
2. Diagnosis and management of rhinitis: Complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology
3. Epidemiology of rhinitis and asthma
4. Overview of comorbid associations of allergic rhinitis
5. The impact of allergic rhinitis on bronchial asthma
6. National guidelines needed to manage rhinitis and prevent complications
7. The pathogenesis of chronic idiopathic urticaria
8. Desloratadine in the treatment of chronic idiopathic urticaria
9. Allergic rhinitis and its impact on asthma
10. 1-receptor antagonist drugs
11. Sedation with "non-sedating" antihistamines: Four prescription-event monitoring studies in general practice
12. Comparative tolerability of second-generation antihistamines
13. A review of the cardiac systemic side effects of antihistamines: Ebastine
14. Update: Clinically significant cytochrome P-450 drug interactions
15. Pathophysiology of the inflammatory response
16. Allergic rhinitis
17. Immunologic basis of antigen-induced airway hyperresponsiveness
18. Allergy and allergic diseases. First of two parts
19. Unique mechanistic features of allergic rhinitis
20. Substance P, calcitonin gene-related peptide, and vasoactive intestinal peptide increase in nasal secretions after allergen challenge in atopic patients
21. Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cells
22. The eosinophilic injury to the mucosa of the airways in the pathogenesis of bronchial asthma
23. Asthma: A dynamic disease of inflammation and repair
24. Augmentation by eosinophils of gelatinase activity in the airway mucosa: Comparative effects as a putative mediator of epithelial injury
25. New insights into the second-generation antihistamines
26. Evaluation and management of allergic rhinitis
27. 1 antihistamines
28. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine
29. Effect of cetirizine and prednisolone on cellular infiltration and cytokine mRNA expression during allergen-induced late cutaneous responses
30. Cellular inflammatory responses during immediate, developing, and established late-phase allergic cutaneous reactions: Effects of cetirizine
31. Cellular inflammatory responses and mediator release during early developing late-phase allergic cutaneous inflammatory responses: Effects of cetirizine
32. Pharmacology and clinical efficacy of desloratadine as an antiallergic and anti-inflammatory drug
33. Desloratadine: A new, non-sedating antihistamine
34. 1-antagonist. 1st communication: Receptor selectivity, antihistaminic activity, and antiallergenic effects
35. Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells
36. 1-receptor antagonist, in patients with seasonal allergic rhinitis. Assessment during the spring and fall allergy seasons
37. Desloratadine reduces nasal congestion in SAR with greater magnitude than fexofenadine, cetirizine, and loratadine
38. Decongestant activity of desloratadine versus placebo in allergic rhinitis: Results from three single-dose, placebo-controlled allergen chamber trials
39. Onset and duration of action of desloratadine after controlled pollen challenges in patients with seasonal allergic rhinitis
40. Once-daily desloratadine reduces the symptoms of perennial allergic rhinitis for at least 4 weeks
41. Desloratadine and pseudophedrine provide similar relief of nasal congestion in patients with seasonal allergic rhinitis
42. 2-agonist use in patients with seasonal allergic rhinitis and concomitant asthma
43. Desloratadine reduces seasonal allergic rhinitis symptoms in patients with seasonal allergic rhinitis and asthma
44. Decongestant effects of desloratadine in patients with seasonal allergic rhinitis and asthma
45. Long-term benefit of desloratadine against seasonal allergic rhinitis symptoms in patients with asthma
46. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: A randomised, double-blind, placebo-controlled study
47. 1 receptor antagonist. 2nd communication: Lack of central nervous system and cardiovascular effects
48. No impairment of flying ability with desloratadine use in healthy volunteers under conditions of simulated cabin pressure
49. max and AUC of fexofenadine by 30%
50. Mizolastine: Antihistaminic activity from preclinical data to clinical evaluation
51. 1 receptor antagonist mizolastine in the rodent
52. Comparative wheal and flare study of mizolastine vs terfenadine, cetirizine, loratadine and placebo in healthy volunteers
53. Anti-inflammatory properties of mizolastine after oral administration on arachidonic acid-induced cutaneous reaction in the rat
54. Efficacy and safety of mizolastine in seasonal allergic rhinitis
55. Comparison of mizolastine with loratadine in the treatment of perennial allergic rhinitis
56. Mizolastine therapy also has an effect on nasal blockade in perennial allergic rhinoconjunctivitis
57. Comparison of the efficacy, safety, and onset of action of mizolastine, cetirizine, and placebo in the management of seasonal allergic rhinoconjunctivitis
58. Mizolastine is effective and well tolerated in long-term treatment of perennial allergic rhinoconjunctivitis
59. Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria
60. Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: Results of the MILOR Study
61. Comparative therapeutic effect and safety of mizolastine and loratadine in chronic idiopathic urticaria
62. One-year treatment of chronic urticaria with mizolastine: Efficacy and safety
63. Inhibition of HERG1 K(+) channels by the novel second-generation antihistamine mizolastine
64. Clinical pharmacokinetics of mizolastine
65. A randomised, double-blind, crossover comparison among cetirizine, levocetirizine, and UCB 28557 on histamine-induced cutaneous responses in healthy adult volunteers
66. Comparison of the effects of levocetirizine and loratadine on histamine-induced wheal, flare, and itch in human skin
67. Effect of levocetirizine on eotaxin-induced eosinophil chemotaxis with and without interlukin-5 priming in vitro
68. Levocetirizine inhibits eotaxin-induced eosinophil transendothelial migration through human dermal or lung microvascular endothelial cells
69. Effect of cetirizine, levocetirizine, and dextrocetirizine on histamine-induced nasal response in healthy adult volunteers
70. Effect of levocetirizine and loratadine on symptom relief in house-dust mite allergic patients exposed to allergen in the Vienna challenge chamber
71. Absorption, distribution, metabolism and excretion of [14C]-levocetirizine, the R enantiomer of cetirizine, in healthy volunteers
72. Absorption and distribution of levocetirizine, the eutomer of cetirizine, administered alone, or as cetirizine to healthy volunteers
73. Norastemizole Sepracor
74. Norastemizole. Antihistamine
75. Dual effect of the anti-allergic astemizole on Ca2+ fluxes in rat basophilic leukemia (RBL-2H3) cells: Release of Ca2+ from intracellular stores and inhibition of Ca2+ release-activated Ca2+ influx
76. Norastemizole (NORA) acts earlier and is more effective for allergic rhinitis symptoms than loratadine (LAT) and placebo (PBO) in an allergen challenge
77. Comparative analysis of the cardiotoxicity proclivities of second-generation antihistamines in an experimental model predictive of adverse clinical ECG effects
78. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole
79. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF)
80. In vitro inhibitory effect of rupatadine on histamine and TNF-alpha release from dispersed canine skin mast cells and the human mast cell line HMC-1
81. Rupatadine exhibits a better profile than ebastine in patients with seasonal allergic rhinitis
82. Effects of rupatadine, a new dual antagonist of histamine and platelet-activating factor receptors, on human cardiac kv1.5 channels
83. 1-receptor and PAF antagonist
84. Effect of topical UCB-28754 on rhinitis provoked by intranasal histamine in the monkey
85. Effect of topical UCB-28754 on rhinitis provoked by intranasal histamine and Ascaris suum in the monkey
86. Effect of topical UCB-28754 nasal spray on the mucociliary transit time in adult healthy volunteers
87. Effect of topical UCB-28754 on the histamine nasal provocation test in healthy adult volunteers
88. Efletirizine nasal spray dose-ranging study in grass pollen-associated allergic rhinoconjunctivitis
89. 1-receptor
90. Effects of an amphoteric antiallergic agent, HSR-609, on antigen-induced late phase nasal eosinophilia in brown Norway rats
91. Effect of a novel anti-allergic agent, HSR-609, on antigen-induced airway hyperresponsiveness in mice
92. Pharmacological studies on the novel antiallergic agent HSR-609: Its effects on behavior in mice and electroencephalograms in rabbits
93. A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: Suppression of histamine-induced wheal and flare response for 24 subjects
94. Inhibitory effect of epinastine on superoxide generation by rat neutrophils
95. A novel antiallergic drug epinastine inhibits IL-8 release from human eosinophils
96. 1 receptor antagonists epinastine, ketotifen and oxatomide in human leukocytes
97. 1 receptor antagonist, epinastine (WAL 801 CL), on isolated human allergic effector cells
98. 1 antiallergic agent epinastine
99. A new model of allergic rhinitis in rats by topical sensitization and evaluation of H(1)-receptor antagonists
100. 1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine
101. 1-receptor occupancy in human subjects treated with epinastine, a second-generation antihistamine
102. Effects of terfenadine, astemizole and epinastine on electrocardiogram in conscious cynomolgus monkeys
103. Pharmacokinetics of epinastine and a possible mechanism for double peaks in oral plasma concentration profiles
104. Ebastine: An update of its use in allergic disorders
105. 1 receptor antagonists
106. 1-receptor antagonist emedastine in healthy volunteers
107. 1-receptor-selective antagonist for ocular use: Receptor binding and second messenger studies
108. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs
109. Involvement of blockade of leukotriene B(4) action in anti-pruritic effects of emedastine in mice
110. Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis
111. Emedastine-ketoconazole: Pharmacokinetic and pharmacodynamic interactions in healthy volunteers
112. Pharmacokinetics of emedastine difumarate, a new anti-histaminic agent in patients with renal impairment